Skip to main content
Equibles

PRQR · ProQR Therapeutics N.V. · Metrics

Track PRQR — free

Use PRQR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PRQR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.26 -0.07 (-5.26%)
Rebalance outlook locked
Market Cap
$187.69M
Shares
141.12M
Volume · Oct 23 1.15M Avg daily vol (3M) 799.65K

PRQR metrics

65 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.33
Market cap
$187.69M

Price action

20 metrics
Price change (1W)
-8.3%
Price change (30D)
-30.0%
Price change (3M)
-25.7%
Price change (6M)
-18.4%
Price change (YTD)
-34.2%
Price change (1Y)
-51.1%
Trailing year
Price change (5Y)
-82.1%
52-week high
$2.91
52-week low
$1.31
Change from 52-week high
-54.3%
Change from 52-week low
+1.5%
Annualized volatility
74.3%
Annualized volatility (3M)
59.3%
Beta
1.8
RSI (14D)
27.4
Price vs SMA 50
-27.8%
Price vs SMA 200
-22.0%
Avg volume (3M)
799,600
Relative volume
0.7
Average dollar volume
$1.49M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
141.12M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
9.0×
reciprocal yield 11.1%
P / book
2.1
reciprocal yield 46.9%
FCF yield
-30.3%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
-233.4%
Trailing 12 months
Net margin
-228.9%
Gross profit (TTM)
—
Operating profit (TTM)
−$42.85M
Net income (TTM)
−$49.04M
Trailing 12 months
Diluted EPS (TTM)
$-0.46
FCF margin
-273.2%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.47

Growth

11 metrics
Revenue growth YoY
+129.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$21.42M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.1%
Year over year · more shares
Revenue CAGR (3Y)
+64.2%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-52.9%
Return on assets
-31.5%
Debt / equity
—
Current ratio
3.5
EBITDA (TTM)
—
Free cash flow (TTM)
−$58.51M
Quick ratio
3.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$133.72M
Total assets
$152.48M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$57.17M
Capital expenditures (TTM)
$1.34M
R&D (TTM)
$53.07M
SG&A (TTM)
—
Stock compensation (TTM)
$5.99M
R&D / revenue
247.8%
Stock compensation / revenue
28.0%

Ownership (13F)

9 metrics
13F filers
70
13F filer change QoQ
+1
Institutional ownership
43.0%
Conviction holders (share of 13F filers)
1.4%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+66.1%
Holder tenure
10.9
Price vs estimated holder cost
-6.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
2.0%
Latest settlement · 5.0 days to cover
Days to cover
5.0d
Short-squeeze score
53 / 100

Insider activity

2 metrics
Net insider buying (90D)
$353,960
Insider-sentiment score
86 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1612940 CUSIP N71542109 13F (30d) 7 filings 7 filers Visit website Investor relations